ArticleCentral-European journal of immunology2026
CircHMGA2 facilitates proliferation and invasion of laryngeal squamous cell carcinoma cells and M2 macrophage polarization
Article in Central-European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Laryngeal squamous cell carcinoma (LSCC) is a malignant tumor of the head and neck. CircRNA High Mobility Group AT-hook 2 (circHMGA2) has cancer-promoting functions. Nevertheless, the role of circHMGA2 in LSCC has not been reported yet. We attempted to illustrate the function and mechanism of circHMGA2 in LSCC. Material and methods: The clinicopathological association between circHMGA2 and LSCC was assessed via the chi-square test. The correlation between circHMGA2 and LSCC patient survival time was determined with Kaplan-Meier analysis. Quantitative real-time PCR was applied to determine circHMGA2 expression in LSCC. Cell Counting Kit-8 assay, Western blot, cell invasion, enzyme-linked immunosorbent assay, and co-culture assays were conducted to evaluate circHMGA2 function in LSCC. Dual-luciferase reporter assay and RNA pull-down were performed to explore the role of circHMGA2 in LSCC. Meanwhile, circHMGA2 function in vivo was evaluated using tumor xenograft experiments, hematoxylin-eosin staining, and immunohistochemical assays. Results: CircHMGA2 was raised in LSCC, and elevated circHMGA2 expression was associated with TNM stage of LSCC patients. Patients with elevated circHMGA2 levels had shorter overall survival. Functionally, circHMGA2 knockdown suppressed LSCC cell proliferation and invasion. Also, circHMGA2 knockdown inhibited M2 macrophage polarization. Mechanistically, circHMGA2 targeted miR-384, and miR-384 targeted ROCK1. Also, ROCK1 level was negatively associated with miR-384 in LSCC tissues, but positively associated with circHMGA2. Moreover, rescue experiments suggested that circHMGA2 knockdown ameliorated LSCC growth via miR-384/ROCK1 and suppressed M2 macrophage polarization through miR-384/ROCK1. Meanwhile, circHMGA2 knockdown inhibited LSCC growth in vivo. Conclusions: CircHMGA2 acts as a competing endogenous RNA, promoting LSCC progression through the miR-384/ROCK1 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.